
Daniel L Jacoby

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6789353/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	13.7	481
2	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. Circulation, 2018, 138, 1387-1398.	1.6	468
3	Empagliflozin in Heart Failure. Circulation, 2020, 142, 1028-1039.	1.6	252
4	Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation, 2020, 141, 1872-1884.	1.6	229
5	Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy. Circulation, 2020, 141, 828-842.	1.6	181
6	Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2020, 75, 2649-2660.	2.8	176
7	Machine Learning Prediction of Mortality and Hospitalization in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 12-21.	4.1	152
8	Genetics of inherited cardiomyopathy. European Heart Journal, 2012, 33, 296-304.	2.2	146
9	Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nature Reviews Cardiology, 2016, 13, 651-675.	13.7	110
10	Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. Circulation: Heart Failure, 2016, 9, e002370.	3.9	109
11	Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy. Circulation, 2021, 143, 606-608.	1.6	109
12	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2021, 397, 2467-2475.	13.7	98
13	Hypochloraemia is strongly and independently associated with mortality in patients with chronic heart failure. European Journal of Heart Failure, 2016, 18, 660-668.	7.1	94
14	Substantial Discrepancy Between Fluid and Weight Loss During Acute Decompensated HeartÂFailure Treatment. American Journal of Medicine, 2015, 128, 776-783.e4.	1.5	88
15	Anisotropic engineered heart tissue made from laser-cut decellularized myocardium. Scientific Reports, 2016, 6, 32068.	3.3	74
16	Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 1988-1996.	2.2	69
17	Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. Circulation, 2021, 143, 1852-1862.	1.6	65
18	Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy. JACC: Heart Failure, 2021, 9, 420-429.	4.1	64

DANIEL L JACOBY

#	Article	IF	CITATIONS
19	Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. JAMA Cardiology, 2020, 5, 83.	6.1	60
20	Real World Use of Hypertonic Saline in Refractory Acute Decompensated HeartÂFailure. JACC: Heart Failure, 2020, 8, 199-208.	4.1	59
21	Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2021, 78, 2518-2532.	2.8	59
22	Application of Whole Exome Sequencing in the Clinical Diagnosis and Management of Inherited Cardiovascular Diseases in Adults. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	55
23	Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack. Circulation, 2017, 135, 1882-1893.	1.6	53
24	Study Design and Rationale of EXPLORER-HCM. Circulation: Heart Failure, 2020, 13, e006853.	3.9	48
25	Spatial and Functional Distribution of <i>MYBPC3</i> Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, 396-405.	3.6	47
26	Incident Atrial Fibrillation Is Associated With <i>MYH7</i> Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e005191.	3.9	46
27	Extracellular Matrix From Hypertrophic Myocardium Provokes Impaired Twitch Dynamics in Healthy Cardiomyocytes. JACC Basic To Translational Science, 2019, 4, 495-505.	4.1	46
28	Feasibility and Efficacy of a Self-Management Intervention for Insomnia in Stable Heart Failure. Journal of Clinical Sleep Medicine, 2015, 11, 1109-1119.	2.6	45
29	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 3932-3944.	2.2	43
30	Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation, 2018, 138, 1210-1220.	1.6	42
31	Disease-specific variant pathogenicity prediction significantly improves variant interpretation in in inherited cardiac conditions. Genetics in Medicine, 2021, 23, 69-79.	2.4	39
32	Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003062.	3.6	38
33	Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment. Cmaj, 2013, 185, 127-134.	2.0	34
34	Effects of Cognitive Behavioral Therapy for Insomnia on Sleep, Symptoms, Stress, and Autonomic Function Among Patients With Heart Failure. Behavioral Sleep Medicine, 2020, 18, 190-202.	2.1	34
35	Clinical Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside Hemodynamic Profiles. PLoS ONE, 2016, 11, e0145881.	2.5	30
36	Cognitive behavioral therapy for insomnia has sustained effects on insomnia, fatigue, and function among people with chronic heart failure and insomnia: the HeartSleep Study. Sleep, 2022, 45, .	1.1	30

Daniel L Jacoby

#	Article	IF	CITATIONS
37	Cognitive behavioral therapy for insomnia in stable heart failure: Protocol for a randomized controlled trial. Contemporary Clinical Trials, 2017, 55, 16-23.	1.8	29
38	Automated multilabel diagnosis on electrocardiographic images and signals. Nature Communications, 2022, 13, 1583.	12.8	29
39	Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis. Journal of Cardiac Failure, 2018, 24, 131-133.	1.7	28
40	Influence of Titration of Neurohormonal Antagonists and Blood Pressure Reduction on Renal Function and Decongestion in Decompensated Heart Failure. Circulation: Heart Failure, 2016, 9, e002333.	3.9	25
41	Patient mutations linked to arrhythmogenic cardiomyopathy enhance calpain-mediated desmoplakin degradation. JCI Insight, 2019, 4, .	5.0	25
42	Inflammation and cardioâ€renal interactions in heart failure: a potential role for interleukinâ€6. European Journal of Heart Failure, 2018, 20, 933-934.	7.1	24
43	Improving Outcomes in INTERMACS Category 1 Patients with Pre-LVAD, Awake Venous-Arterial Extracorporeal Membrane Oxygenation Support. ASAIO Journal, 2019, 65, 819-826.	1.6	22
44	Effects of Cognitive Behavioral Therapy for Insomnia on Sleep-Related Cognitions Among Patients With Stable Heart Failure. Behavioral Sleep Medicine, 2019, 17, 342-354.	2.1	20
45	Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy. Circulation, 2022, 145, 1238-1253.	1.6	20
46	Left atrial fibrosis correlates with extent of left ventricular myocardial delayed enhancement and left ventricular strain in hypertrophic cardiomyopathy. International Journal of Cardiovascular Imaging, 2019, 35, 1309-1318.	1.5	19
47	Familial dilated cardiomyopathy diagnosis is commonly overlooked at the time of transplant listing. Journal of Heart and Lung Transplantation, 2016, 35, 474-480.	0.6	18
48	Danicamtiv Enhances Systolic Function and Frank‣tarling Behavior at Minimal Diastolic Cost in Engineered Human Myocardium. Journal of the American Heart Association, 2021, 10, e020860.	3.7	18
49	Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation. Journal of General Physiology, 2021, 153, .	1.9	15
50	Evaluation of Case Volumes of a Heart Transplant Program and Short-term Outcomes After Changes in the United Network for Organ Sharing Donor Heart Allocation System. JAMA Network Open, 2020, 3, e2017513.	5.9	14
51	The Impact of Donor and Recipient Renal Dysfunction on Cardiac Allograft Survival: Insights Into Reno-Cardiac Interactions. Journal of Cardiac Failure, 2016, 22, 368-375.	1.7	11
52	Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies. PLoS ONE, 2021, 16, e0247789.	2.5	11
53	Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. Genetics in Medicine, 2021, 23, 1281-1287.	2.4	11
54	Evaluating Recruitment Strategies for a Randomized Clinical Trial with Heart Failure Patients. Western Journal of Nursing Research, 2020, 43, 019394592097022.	1.4	10

DANIEL L JACOBY

#	Article	IF	CITATIONS
55	Impact of Obesity on Heart Transplantation Outcomes. Journal of the American Heart Association, 2021, 10, e021346.	3.7	10
56	Psychological stress in heart failure: a potentially actionable disease modifier. Heart Failure Reviews, 2021, 26, 561-575.	3.9	9
57	Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) in a young female athlete at 36 weeks gestation: a case report. Pathology Research and Practice, 2017, 213, 1302-1305.	2.3	8
58	Risk score for the exclusion of arrhythmic events in arrhythmogenic right ventricular cardiomyopathy at first presentation. International Journal of Cardiology, 2019, 290, 100-105.	1.7	8
59	Perceived Stress, Subjective, and Objective Symptoms of Disturbed Sleep in Men and Women with Stable Heart Failure. Behavioral Sleep Medicine, 2021, 19, 363-377.	2.1	8
60	Variability in Blood Pressure Assessment in Patients Supported with the HeartMate 3TM. ASAIO Journal, 2022, 68, 374-383.	1.6	8
61	Symptom Cluster Profiles Among Adults with Insomnia and Heart Failure. Behavioral Sleep Medicine, 2023, 21, 150-161.	2.1	8
62	The Genetic Challenges and Opportunities in Advanced Heart Failure. Canadian Journal of Cardiology, 2015, 31, 1338-1350.	1.7	7
63	Day-to-day Relationships between Physical Activity and Sleep Characteristics among People with Heart Failure and Insomnia. Behavioral Sleep Medicine, 2021, 19, 602-614.	2.1	6
64	Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy. American Heart Journal, 2022, 246, 21-31.	2.7	6
65	Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use. Clinical Pharmacology and Therapeutics, 2021, 110, 777-785.	4.7	5
66	Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond. European Journal of Internal Medicine, 2022, 102, 1-7.	2.2	5
67	Sleep Characteristics, Mood, Somatic Symptoms, and Self-Care Among People With Heart Failure and Insomnia. Nursing Research, 2022, 71, 189-199.	1.7	4
68	Mulibrey Nanism Syndrome: A Case for Heart Transplantation. Annals of Thoracic Surgery, 2020, 109, e115-e117.	1.3	3
69	Underuse of statins for secondary prevention of atherosclerotic cardiovascular disease events among ambulatory surgical patients. Preventive Medicine Reports, 2020, 18, 101085.	1.8	3
70	Differential Impact of Class I and Class II Panel Reactive Antibodies on Post-Heart Transplant Outcomes. Journal of Cardiac Failure, 2021, 27, 40-47.	1.7	3
71	Impact of Preoperative Lymphopenia on Survival Following Left Ventricular Assist Device Placement. ASAIO Journal, 2021, 67, 650-657.	1.6	3
72	The Yale Roadmap for Health Psychology and Integrated Cardiovascular Care Health Psychology, 2022, 41, 779-791.	1.6	3

DANIEL L JACOBY

#	Article	IF	CITATIONS
73	Natural History of End-stage LV Dysfunction: Has It Improved from the Classic Franciosa and Cohn Graph?. Cardiology Clinics, 2011, 29, 485-495.	2.2	2
74	Mavacamten for hypertrophic obstructive cardiomyopathy – Authors' reply. Lancet, The, 2021, 397, 369-370.	13.7	2
75	Novel Myosin-Based Therapies in Hypertrophic Cardiomyopathy. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.9	2
76	When the money is not in the bank. European Heart Journal, 2016, 37, 1847-1849.	2.2	1
77	Participation in thrill-seeking activities by patients with hypertrophic cardiomyopathy: Individual preferences, adverse events and physician attitude. American Heart Journal, 2019, 214, 28-35.	2.7	1
78	The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic <i>transthyretin</i> expression. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 110-119.	3.0	1
79	Placing heart failure and diastolic dysfunction in the case of cardiac amyloid into perspective: what an amyloid heart really looks like. International Journal of Cardiovascular Imaging, 2018, 34, 543-544.	1.5	0
80	Advanced Cardiac Imaging and the Complexity of Diagnosing Cardiac Sarcoidosis. Circulation: Cardiovascular Imaging, 2019, 12, e009275.	2.6	0
81	342 CBT-I Has Sustained Effects on Insomnia Versus Heart-Failure Self-Management Education among Adults with Chronic Heart Failure. Sleep, 2021, 44, A136-A137.	1.1	0
82	Brain Natriuretic Peptide (BNP) Elevations In Allogeneic Stem Cell Transplant (ASCT) Recipients at the Time of WBC Engraftment. Correlation with Engraftment Syndrome and Cardiac Dysfunction Blood, 2010, 116, 1309-1309.	1.4	0